CD33 $ BiTE^{®} $ molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
Abstract Bispecific T-cell engager ($ BiTE^{®} $) molecules recruit T cells to cancer cells through CD3ε binding, independently of T-cell receptor (TCR) specificity. Whereas physiological T-cell activation is dependent on signal 1 (TCR engagement) and signal 2 (co-stimulation), BiTE molecule-mediated T-cell activation occurs without additional co-stimulation. As co-stimulatory and inhibitory molecules modulate the strength and nature of T-cell responses, we studied the impact of the expression profile of those molecules on target cells for BiTE molecule-mediated T-cell activation in the context of acute myeloid leukemia (AML). Accordingly, we created a novel in vitro model system using murine Ba/F3 cells transduced with human CD33 ± CD86 ± PD-L1. T-cell fitness was assessed by T-cell function assays in co-cultures and immune synapse formation by applying a CD33 BiTE molecule (AMG 330). Using our cell-based model platform, we found that the expression of positive co-stimulatory molecules on target cells markedly enhanced BiTE molecule-mediated T-cell activation. The initiation and stability of the immune synapse between T cells and target cells were significantly increased through the expression of CD86 on target cells. By contrast, the co-inhibitory molecule PD-L1 impaired the stability of BiTE molecule-induced immune synapses and subsequent T-cell responses. We validated our findings in primary T-cell-AML co-cultures, demonstrating a PD-L1-mediated reduction in redirected T-cell activation. The addition of the immunomodulatory drug (IMiD) lenalidomide to co-cultures led to stabilization of immune synapses and improved subsequent T-cell responses. We conclude that target cells modulate CD33 BiTE molecule-dependent T-cell activation and hence, combinatorial strategies might contribute to enhanced efficacy..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
---|---|
Enthalten in: |
Cancer immunology immunotherapy - 72(2023), 7 vom: 11. Apr., Seite 2499-2512 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Marcinek, Anetta [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
Acute myeloid leukemia |
Anmerkungen: |
© The Author(s) 2023 |
---|
doi: |
10.1007/s00262-023-03439-x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2143839162 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC2143839162 | ||
003 | DE-627 | ||
005 | 20240118092015.0 | ||
007 | tu | ||
008 | 240118s2023 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s00262-023-03439-x |2 doi | |
035 | |a (DE-627)OLC2143839162 | ||
035 | |a (DE-He213)s00262-023-03439-x-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 44.00 |2 bkl | ||
100 | 1 | |a Marcinek, Anetta |e verfasserin |4 aut | |
245 | 1 | 0 | |a CD33 $ BiTE^{®} $ molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © The Author(s) 2023 | ||
520 | |a Abstract Bispecific T-cell engager ($ BiTE^{®} $) molecules recruit T cells to cancer cells through CD3ε binding, independently of T-cell receptor (TCR) specificity. Whereas physiological T-cell activation is dependent on signal 1 (TCR engagement) and signal 2 (co-stimulation), BiTE molecule-mediated T-cell activation occurs without additional co-stimulation. As co-stimulatory and inhibitory molecules modulate the strength and nature of T-cell responses, we studied the impact of the expression profile of those molecules on target cells for BiTE molecule-mediated T-cell activation in the context of acute myeloid leukemia (AML). Accordingly, we created a novel in vitro model system using murine Ba/F3 cells transduced with human CD33 ± CD86 ± PD-L1. T-cell fitness was assessed by T-cell function assays in co-cultures and immune synapse formation by applying a CD33 BiTE molecule (AMG 330). Using our cell-based model platform, we found that the expression of positive co-stimulatory molecules on target cells markedly enhanced BiTE molecule-mediated T-cell activation. The initiation and stability of the immune synapse between T cells and target cells were significantly increased through the expression of CD86 on target cells. By contrast, the co-inhibitory molecule PD-L1 impaired the stability of BiTE molecule-induced immune synapses and subsequent T-cell responses. We validated our findings in primary T-cell-AML co-cultures, demonstrating a PD-L1-mediated reduction in redirected T-cell activation. The addition of the immunomodulatory drug (IMiD) lenalidomide to co-cultures led to stabilization of immune synapses and improved subsequent T-cell responses. We conclude that target cells modulate CD33 BiTE molecule-dependent T-cell activation and hence, combinatorial strategies might contribute to enhanced efficacy. | ||
650 | 4 | |a Acute myeloid leukemia | |
650 | 4 | |a Bispecific antibodies | |
650 | 4 | |a Immune synapse | |
650 | 4 | |a Costimulation (CD86) | |
650 | 4 | |a Checkpoint molecule (PD-L1) | |
700 | 1 | |a Brauchle, Bettina |4 aut | |
700 | 1 | |a Rohrbacher, Lisa |4 aut | |
700 | 1 | |a Hänel, Gerulf |4 aut | |
700 | 1 | |a Philipp, Nora |4 aut | |
700 | 1 | |a Märkl, Florian |4 aut | |
700 | 1 | |a Strzalkowski, Thaddäus |4 aut | |
700 | 1 | |a Lacher, Sonja M. |4 aut | |
700 | 1 | |a Udiljak, Dragica |4 aut | |
700 | 1 | |a Spiekermann, Karsten |4 aut | |
700 | 1 | |a Theurich, Sebastian |4 aut | |
700 | 1 | |a Kobold, Sebastian |4 aut | |
700 | 1 | |a Kischel, Roman |4 aut | |
700 | 1 | |a James, John R. |4 aut | |
700 | 1 | |a Bücklein, Veit L. |4 aut | |
700 | 1 | |a Subklewe, Marion |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer immunology immunotherapy |d Springer Berlin Heidelberg, 1976 |g 72(2023), 7 vom: 11. Apr., Seite 2499-2512 |w (DE-627)129442712 |w (DE-600)195342-4 |w (DE-576)014812193 |x 0340-7004 |7 nnns |
773 | 1 | 8 | |g volume:72 |g year:2023 |g number:7 |g day:11 |g month:04 |g pages:2499-2512 |
856 | 4 | 1 | |u https://doi.org/10.1007/s00262-023-03439-x |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_2018 | ||
912 | |a GBV_ILN_4277 | ||
936 | b | k | |a 44.00 |q VZ |
951 | |a AR | ||
952 | |d 72 |j 2023 |e 7 |b 11 |c 04 |h 2499-2512 |